Abstract:Background A disintegrin and metallopeptidase domain 8 (ADAM8) may be closely related to the progress of cardiovascular diseases. ADAM8 was first found in macrophages from mice, and ADAM family is closely related to the secretion function of macrophages. Therefore, ADAM8 may affect the process of myocardial infarction (MI) by regulating macrophage function. Purpose This study aims to explore how ADAM8 regulating the function of macrophages to inhibit the cardiac repair after MI. Methods CRISPR/Cas9 system was used to generate macrophage-specific ADAM8 knockout mice (ADAM8flox/flox,Lyz2-Cre, ADAM8 mKO) and ADAM8flox/flox (control) . Bone marrow transplantation was performed and macrophage-specific ADAM8 overexpressed adeno-associated virus (AAV6-CD68-Adam8) was generated. Proteomics of hearts and RNA-sequencing of bone marrow derived macrophages (BMDM) was performed. Cellular and molecular assays were used to discover the underlying mechanisms of ADAM8 function. Results (1) ADAM8 in serum of AMI patients was significantly higher than control group. ADAM8 was highly expressed in cardiac macrophages after day 3 of AMI. (2) Compared with the control group, the expression of CD31 and VEGFA in the infarcted myocardium was significantly increased in ADAM8 mKO mice, indicating enhanced angiogenesis. The cardiac fibrosis was decreased and heart function was improved in ADAM8 mKO group. ADAM8 overexpression can reverse the increase of angiogenesis caused by ADAM8 mKO and promote cardiac fibrosis in mice. The bone marrow transplantation experiments also showed that donor of ADAM8 mKO mice had increased angiogenesis and reduced cardiac fibrosis in the infarcted area. (3) The proteomics of hearts in AMI day 14, showed the Cardiac muscle contraction pathway and the Citrate cycle (TCA cycle) pathway in ADAM8 mKO mice were both increased significantly, indicating improved cardiac function and maintained the metabolic stability of heart after MI. Myocardial injection in situ of anti-VEGFA antibody can reverse the angiogenesis induced by ADAM8 mKO, and deteriorate heart function. (4) The supernatants and protein lysates of ADAM8 KO BMDM showed the decreased level of VEGFA, and IL-1β/IL-18. (5) RNA-sequencing showed that AMPK signaling pathway and autophagy pathway were both significantly increased in ADAM8 KO BMDM treated with LPS. p-AMPK/AMPK and autophagy-related molecules were obviously elevated in ADAM8 KO BMDM. Application of autophagy inhibitor 3-Methyladenine (3-MA) could reverse ADAM8 KO induced secretion of VEGFA and IL-1β/IL-18. Conclusions Our study has discovered ADAM8 as a new regulator of myocardial infarction. ADAM8 KO may promoting VEGFA secretion and inhibiting inflammatory factors secretion of macrophages via AMPK/autophagy pathway, further promoting angiogenesis and reducing fibrosis of infarcted myocardium, and attenuating heart function and adverse remodeling. ADAM8 may be a new target for treating myocardial infarction.Schematic diagram

ADAM17, A Key Player of Cardiac Inflammation and Fibrosis in Heart Failure Development During Chronic Catecholamine Stress

The Downregulation of ADAM17 Exerts Protective Effects Against Cardiac Fibrosis by Regulating Endoplasmic Reticulum Stress and Mitophagy

ADAMTS16 Activates Latent TGF-β, Accentuating Fibrosis and Dysfunction of the Pressure-Overloaded Heart.

A Disintegrin and Metalloprotease-17 Regulates Pressure Overload–Induced Myocardial Hypertrophy and Dysfunction Through Proteolytic Processing of Integrin Β1

Cardiomyocyte A Disintegrin and Metalloproteinase 17 (ADAM17) is Essential in Post–Myocardial Infarction Repair by Regulating Angiogenesis

Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling

ADAMTS13 Inhibits Oxidative Stress and Ameliorates Progressive Chronic Kidney Disease Following Ischaemia/reperfusion Injury.

A Disintegrin and Metalloprotease-22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway.

ADAM17 knockdown mitigates while ADAM17 overexpression aggravates cardiac fibrosis and dysfunction via regulating ACE2 shedding and myofibroblast transformation

Loss of ADAM15 Exacerbates Transition to Decompensated Myocardial Hypertrophy and Dilation Through Activation of the Calcineurin Pathway

ADAM23 in Cardiomyocyte Inhibits Cardiac Hypertrophy by Targeting FAK - AKT Signaling.

Emerging roles for the ADAMTS-like family of matricellular proteins in cardiovascular disease through regulation of the extracellular microenvironment

ADAM8 deficiency in macrophages promotes cardiac repair after myocardial infarction via ANXA2-mTOR-autophagy pathway

Cardiomyocyte-specific knockout of ADAM17 ameliorates left ventricular remodeling and function in diabetic cardiomyopathy of mice

The Synergy of ADAM17-Induced Myocardial Inflammation and Metabolic Lipids Dysregulation During Acute Stress: New Pathophysiologic Insights Into Takotsubo Cardiomyopathy

ADAMTS-7, a Novel Proteolytic Culprit in Vascular Remodeling.

Expression and significance of ADAMTS-4 in myocardium in patients with heart failure

ADAM8 Deficiency in Macrophages Promotes Angiogenesis to Antagonize Post-Myocardial Infarction Cardiac Injury

ADAM15 in Fibroblasts: Improving the Matrix Remodeling by Blocking the Action of Transforming Growth Factor-β1

Beta-adrenoceptor Signaling Pathways Mediate Cardiac Pathological Remodeling.

The Protease ADAM17 at the Crossroads of Disease: Revisiting its Significance in Inflammation, Cancer, and Beyond